retatrutide phase 2 trial results weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide Achieves Up to 30.3%

Saxenda specifically licensed for weight management) [2] [5] Dulaglutide (Trulicity for diabetes only) Exenatide (Byetta, Bydureon for diabetes only) Oral semaglutide (Rybelsus for diabetes only) These medications are administered via subcutaneous injection (except Rybelsus), with dosing frequencies ranging from daily to weekly depending on the specific formulation

Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP receptor agonist

In addition, in the vast majority of these studies, liraglutide was used at low or medium doses, while it is well known that some effects, in particular weight loss, are dose-dependent and more pronounced at the maximum dose

Taking your drops at the same time every day is more important than which specific time you choose

You should also have a strategy for managing possible mild side effects like nausea

Early real-world data suggest promising results in post-bariatric patients, though formal trials are limited